Natural sesquiterpene lactones are active against Leishmania mexicana

Journal of Parasitology

Volumn 94, Issue 5, 2008, Pages 1143-1149

  Barrera, Patricia A ^a   Jimenez Ortiz, Verónica ^a,b   Tonn, Carlos ^a,c   Giordano, Oscar ^a,c   Galanti, Norbel ^a,b   Sosa, Miguel A ^a  

^a Instituto de Histologia y Embriologia   (Argentina)

^b UNIVERSITY OF CHILE   (Chile)

^c UNIVERSIDAD NACIONAL DE SAN LUIS   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

DEHYDROLEUCODINE; HELENALIN; KETOCONAZOLE; MEXICANIN; SESQUITERPENE; UNCLASSIFIED DRUG;

DISEASE TREATMENT; DNA; ELECTROKINESIS; ESTER; IDENTIFICATION METHOD; INHIBITION; LEISHMANIASIS; LIFE CYCLE; MAMMAL; PROTOZOAN; TERPENE; TOXICITY TEST;

ANIMAL CELL; ARTICLE; CELL INVASION; CELL VACUOLE; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DNA FRAGMENTATION; DRUG EFFECT; ELECTROPHORESIS; GROWTH INHIBITION; IC 50; LEISHMANIA MEXICANA; LIFE CYCLE; MICROTUBULE; NICK END LABELING; NONHUMAN; PROMASTIGOTE; VERO CELL;

ANIMALS; ANTIPROTOZOAL AGENTS; ARTEMISIA; ASTERACEAE; CERCOPITHECUS AETHIOPS; DNA FRAGMENTATION; DNA, PROTOZOAN; IN SITU NICK-END LABELING; LACTONES; LEISHMANIA MEXICANA; MICROSCOPY, ELECTRON, TRANSMISSION; SESQUITERPENES; VERO CELLS;

LEISHMANIA MEXICANA; MAMMALIA;

EID: 54349102725     PISSN: 00223395     EISSN: None     Source Type: Journal    
DOI: 10.1645/GE-1501.1     Document Type: Article

References (26)

1. BERMAN, J. D. 1997. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clinical Infectious Diseases 24: 684-703.
2. BRENGIO, S. D., S. A. BELMONTE, E. GUERREIRO, O. S. GIORDANO, E. O. PIETROBON, AND M. A. SOSA. 2000. The sesquiterpene lactone dehydroleucodine (DhL) affects the growth of cultured epimastigotes of Trypanosoma cruzi. Journal of Parasitology 86: 407-412.
3. CAMPBELL, W. C. 1986. The chemotherapy of parasitic infections. Journal of Parasitology 72: 45-61.
4. CROFT, S. L. 2001. Monitoring drug resistance in leishmaniasis. Tropical Medicine & International Health 6: 899-905.
5. DAVIS, A. J., H. W. MURRAY, AND E. HANDMAN. 2004. Drugs against leishmaniasis: A synergy of technology and partnerships. Trends in Parasitology 20: 73-76.
6. FRANCOIS, G., AND T. M. PASSREITER. 2004. Pseudoguaianolide sesquiterpene lactones with high activities against the human malaria parasite Plasmodium falciparum. Phytotherapy Research 18: 184-186.
7. GIORDANO, O. S., E. GUERREIRO, M. J. PESTCHANKER, J. GUZMAN, D. PASTOR, AND T. GUARDIA. 1990. The gastric cytoprotective effect of several sesquiterpene lactones. Journal of Natural Products 53: 803-809.
8. HANDMAN, E. 1999. Cell biology of Leishmania. Advances in Parasitology 44: 1-39.
9. _. 2001. Leishmaniasis: Current status of vaccine development. Clinical Microbiology Reviews 14: 229-243.
10. HERWALDT, B. L. 1999. Leishmaniasis. Lancet 354: 1191-1199.
11. 2+ pool content and signaling and expression of a calcium pump are linked to virulence in Leishmania mexicana amazonensis amastigotes. The Journal of Biological Chemistry 272: 9464-9473.
12. HUANG, P. R., Y. M. YEH, AND T. C. WANG. 2005. Potent inhibition of human telomerase by helenalin. Cancer Letter 227: 169-174.
13. JIMENEZ-ORTIZ, V., S. D. BRENGIO, O. GIORDANO, C. TONN, M. SÁNCHEZ, M. H. BURGOS, AND M. A. SOSA. 2005. The trypanocidal effect of sesquiterpene lactones helenalin and mexicanin on cultured epimastigotes. Journal of Parasitology 91: 170-174.
14. KILLICK-KENDRICK, R. 1990. The life cycle of Leishmania in the sandfly with special reference to the form infective to the vertebrate host. Annales de Parasitologie Humaine et Comparée 65: 37-42.
15. KUPCHAN, S. M., M. A. EAKIN, AND A. M. THOMAS. 1971. Tumor inhibitors. Structure cytotoxicity relationship among the sesquiterpene lactones. Journal of Medicinal Chemistry 14: 1147-1152.
16. LEE, I. H., A. H. HALL, E. C. MAR, C. O. STARNES, S. A. ELGEBALY, T. G. WADDELL, R. I. HADGRAFT, C. G. RUFFNER, AND I. WEIDNER. 1977. Sesquiterpene antitumor agents: Inhibitors of cellular metabolism. Science 196: 533-535.
17. PRITCHARD, J. F., M. JURIMA-ROMET, M. L. REIMER, E. MORTIMER, B. ROLFE, AND M. N. CAYEN. 2003. Making better drugs: Decision gates in non-clinical drug development. Nature Reviews. Drug Discovery 2: 542-553.
18. ROBLES, M., M. AREGULLIN, J. WEST, AND E. RODRIGUEZ. 1995. Recent studies on the zoopharmacognosy, pharmacology, and neurotoxicology of sesquiterpene lactones. Planta Medica 61: 199-203.
19. SCHMIDT, T., G. BRUN, G. WILLHUN, AND S. A. KHALID. 2002. Antitrypanocidal activity of helenalin and some structurally related sesquiterpene lactones. Planta Medica 68: 750-751.
20. SUNDAR, S. 2001a. Drug resistance in Indian visceral leishmaniasis. Tropical Medicine & International Health 6: 849-854.
21. _. 2001b. Treatment of visceral leishmaniasis. Medical Microbiology and Immunology (Berl) 190: 89-92.
22. _, T. K. JHA, C. P. THAKUR, J. ENGEL, H. SINDERMANN, C. FISCHER, K. JUNGE, A. BRYCESON, AND K. H. BERMAN. 2002. Oral miltefosine for Indian visceral leishmaniasis. The New England Journal of Medicine 347: 1739-1746.
23. TIUMAN, T. S., T. UEDA-NAKAMURA, D. A. GARCÍA CORTEZ, B. PRADO DIAS FILHO, J. A. MORGADO-DÍAZ, W. DE SOUZA, AND C. V. NAKAMURA. 2005. Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium. Antimicrobial Agents and Chemotherapy 49: 176-182.
24. WALLER, R. F., AND M. J. MCCONVILLE. 2002. Developmental changes in lysosome morphology and function of Leishmania parasites. International Journal for Parasitology 32: 1435-1445.
25. YAKUBU, M. A., S. MAJUMDER, AND F. K IERSZENBAUM. 1994. Changes in Trypanosoma cruzi infectivity by treatments that affect calcium ion levels. Molecular and Biochemical Parasitology 66: 119-125.
26. ZHANG, S., Y. K. WON, C. N. ONG, AND H. M. SHEN. 2005. Anti-cancer potential of sesquiterpene lactones: Bioactivity and molecular mechanisms. Current Medicinal Chemistry Anticancer Agents 5: 239-249.